'Regenerative Medicine Market Will Reach $1.4 Billion in 2012' States Visiongain Report

English
7 Pages
Read
Download
Downloading requires you to have access to the YouScribe library
Learn all about the services we offer

Description

'Regenerative Medicine Market Will Reach $1.4 Billion in 2012' States Visiongain Report PR Newswire LONDON, September 11, 2012 LONDON, September 11, 2012 /PRNewswire/ -- A new report by visiongain predicts that the overall world market for translational regenerative medicine will reach $1.4bn in 2012. That revenue forecast and others appear in Translational Regenerative Medicine Market Prospects 2012-2022, published in September 2012. Visiongain is a business information provider based in London, UK. Visiongain forecasts that the overall regenerative medicine market will multiply in size from 2012 to 2022. The regenerative medicine industry is in its infancy; however marketed products have achieved commercial success. Visiongain believes the strength of the regenerative medicine market is its potential to treat a plethora of diseases. Growth of the market will be driven by targeting serious, prevalent disorders such as cancer, cardiovascular disease and diabetes. In these areas, the potential for regenerative medicine technologies is vast, and regulatory and cultural uncertainties about the field will not derail its progress from 2012 to 2022. Dr Peter Williamson, a pharmaceutical industry analyst in visiongain, said: "Regenerative medicine is a market with huge potential. The key to its future lies in the successful approval and commercialisation of new products.

Subjects

Informations

Published by
Reads 198
Language English
Report a problem
'Regenerative Medicine Market Will Reach $1.4 Billion in 2012' States Visiongain Report
PR Newswire LONDON, September 11, 2012
LONDON,September 11, 2012/PRNewswire/ --A new report by visiongain predicts that the overall world market for translational regenerative medicine will reach$1.4bnin 2012. That revenue forecast and others appear in Translational Regenerative Medicine Market Prospects 2012-2022, published inSeptember 2012. Visiongain is a business information provider based inLondon, UK. Visiongain forecasts that the overall regenerative medicine market will multiply in size from 2012 to 2022. The regenerative medicine industry is in its infancy; however marketed products have achieved commercial success. Visiongain believes the strength of the regenerative medicine market is its potential to treat a plethora of diseases. Growth of the market will be driven by targeting serious, prevalent disorders such as cancer, cardiovascular disease and diabetes. In these areas, the potential for regenerative medicine technologies is vast, and regulatory and cultural uncertainties about the field will not derail its progress from 2012 to 2022. Dr Peter Williamson, a pharmaceutical industry analyst in visiongain, said: "Regenerative medicine is a market with huge potential. The key to its future lies in the successful approval and commercialisation of new products. We have already seen commercial success in the tissue engineering sector with products such as Dermagraft and Apligraf. It is important that companies, reimbursement agencies and regulatory authorities learn lessons from these achievements, ultimately guiding efficient developmental processes. In addition, advances in the scientific understanding of cellular mechanisms and how they aid and influence regeneration will strengthen these processes. "Our study notes that widespread commercialisation will be challenging during the forecast period 2012 to 2022. However, these challenges will be overcome by the maturing market, investment from pharmaceutical companies and the creation of regenerative medicine centres. In addition, there are growing numbers of regenerative medicine start-up companies and research and development (R&D) for regenerative medicine is strong." Visiongain's report shows revenue forecasts to 2022 at overall world market, submarket, product and regional level. It forecasts these world-level submarkets:
Tissue-engineered products Stem cell applications Gene therapy Other uses.
The investigation predicts revenues of leading products in the market: Apligraf, Dermagraft, DeNovo NT and Osteocel Plus. Research, data and analyses cover activities of Shire Regenerative Medicine, Advanced Cell Technology, Athersys, Mesoblast, Geron and other companies.
That study discusses R&D and commercial news, shows research interviews and predicts revenues to 2022 in leading regional markets. The work analyses the United States,Europe(EU,Norway,SwitzerlandandIceland),Asia Pacific (Japan,China,IndiaandSouth Korea), and the rest of the world (as a group), includingBrazilandRussia. Translational Regenerative Medicine: Market Prospects 2012-2022 adds to visiongain's range of analytical reports on industries and markets in healthcare. For sample pages and further information concerning the Translational Regenerative Medicine: Market Prospects 2012-2022 please visit: http://www.visiongain.com/Report/886/Translational-Regenerative-Medicine-Market-Prospects-2012-2022 For an executive summary of this report or to order it today please contact: Email: Sara Peerun on sara.peerun@visiongainglobal.com Tel: +44(0)20-7336-6100 Companies Listed Aastrom Biosciences Advanced BioHealing Advanced Cell Technology Advanced Technologies and Regenerative Medicine Aldagen AlloSource AlphaTec Spine ALS Therapy Development Institute (US) Altrika Amedica American Academy of Ophthalmology Amgen Amorcyte Amsterdam Molecular Therapeutics (AMT) AnGes MG Angioblast Systems Angiotech AnorMED Anterogen Apceth ArBlast ARCH Venture Partners Ark Therapeutics AstraZeneca Athersys Avita Medical AxoGen Baxter Healthcare Baylor College of Medicine Beike Biotechnology Benda Pharmaceutical Beth Israel Deaconess Medical Center BioD LLC BioDlogics Biogenea Pharmaceuticals Bioheart
BioMed Realty Trust BioSante Pharmaceuticals BioTime BioTissue bluebird bio Boehringer Ingelheim BrainStorm BresaGen Brown University California Institute of Regenerative Medicine (CIRM) Canaan Partners Capricor Cardio3 BioSciences Cardiogenesis Corporation Catalan Institution for Research and Advanced Studies Cellartis CellCoTec Cellerant Therapeutics Cellerix Cellonis Biotechnology CellSeed Center for Commercialization of Regenerative Medicine (Canada) Center for Medicare and Medicaid Services (US) Cephalon Ceregene CHA Biotech Cha General Hospital,Seoul Children's Hospital ofPhiladelphia Chinese Academy of Sciences Chinese Ministry of Science and Technology Clinical Cell Culture co.don AG Cold Genesys Committee for Advanced Therapies (CAT) Crawford Healthcare Cryo Center Saint-Petersburg CyThera Cytori Therapeutics Daiichi Sankyo Dendreon Department of Health (UK) DePuy Mitek Drugs Controller General ofIndia(DCGI) Eli Lilly Emory University Epeius Biotechnologies European Medicines Agency (EMA) EyeCyte FCB-Pharmicell Fibrocell Science Food and Drug Administration (US FDA)
Forbion Capital Partners Gamida Cell Garnet Biotherapeutics Gemabank Genentech Genethon Genetic Engineering Approval Committee (GEAC) GenVec Genzyme Geron Geron Bio-Med GlaxoSmithKline Hadassah Medical Organization Harvard Medical School HealthCanada Hefei Meifu Bio-Tech Histogenics Humacyte Human Stem Cell Institute Ilika ImmunoCellular Therapeutics Integra Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami International Society for Stem Cell Research (ISSCR) Introgen ISTO Technologies Ixion Biotechnology Japan Patent Office (JPO) Japanese Society for Regenerative Medicine (JSRM) Japanese Tissue Engineering Co Jennerex Biotherapeutics John Hopkins Cancer Centre Johnson & Johnson (J&J) Juvenile Diabetes Research Foundation (JDRF) Kanazawa University Kinetic Concepts Kobe Pharmaceutical University Korea Food and Drug Administration (KFDA) LecTec Corporation LifeCell Lonza Lund University Stem Cell Center Massachusetts Institute of Technology (MIT) Massey Cancer Center, Virginia Commonwealth University Medical Research Council (UK) Medicines and Healthcare Products Regulatory Agency (MHRA, UK) Medipost MediStem Medtronic Merck & Co.
Merck Millipore (a division of Merck KGaA) Mesoblast Ministry of Health (China) Ministry of Health, Labour and Welfare (MHLW)Japan MolMed Moorfields Eye Hospital (UK) Motor Neurone Disease Association (MNDA, UK) Muscular Dystrophy Association (US) Musculoskeletal Transplant Foundation Myriad Genetics Mytogen NagoyaUniversity National Cancer Institute National Institute for Health and Clinical Excellence (NICE, UK) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) National Institutes of Health (NIH) National Tissue Engineering Center (NTEC)China NeoStem Neuralstem Neurologix Nippon Zoki Pharmaceutical Northern Therapeutics Northwestern University Novartis Novo Nordisk Novocell NuVasive OJSC HSCI (Human Stem Cells Institute) OncoCyte Opexa Therapeutics OrbusNeich Organ Procurement and Transplantation Network (OPTN) Organogenesis Orthofix Osiris Therapeutics Oxford BioMedica Parcell Laboratories Pervasis Therapeutics Pfizer Pharmacells Pharmaceutical and Medical Devices Agency (PMDA)Japan Philippines Bureau of Food and Drugs Pluristem Therapeutics ProChon Biotech PsiOxus Therapeutics Queen's University Belfast RegenTec Reliance Life Sciences ReNeuron Review Committee of Genetic Manipulation (RCGM) Roche
Russian Ministry of Healthcare and Social Development Rutgers University Safeguard Scientifics Sanofi Saudi Food and Drug Authority (SFDA) Shanghai Qisheng Shanghai Sunway Biotech Shenzhen SiBiono GeneTech Shire Pharmaceuticals Shire Regenerative Medicine Skye Orthobiologics Southern General Hospital (Scotland) SpineSmith Partners St. Jude's Children Research Hospital State Food and Drug Administration (SFDA)China Stem Cell Research Center, Peking University StemCells StemGen Stempeutics Research SUNY Upstate Medical University (Japan) SynBio Takara Bio Targeted Genetics Corporation TCA Cellular Therapy Tel Aviv University Tengion Texas Heart Institute Third Rock Ventures TiGenix Tissue Genesis Translational Research Informatics Center (Foundation for Biomedical Research and Innovation) TVM Capital UniQure University College London (UCL) University of California, Los Angeles (UCLA) University of Copenhagen University ofGeneva University of Glasgow University of Leuven University of Michigan University of Modena Centre for Regenerative Medicine University of Pennsylvania University ofYork US Department of Defense US Government Accountability Office (USGAO) ViaCyte Vical Vindon Scientific Virginia Commonwealth University Massey Cancer Center Visomed
Wake Forest Institute for Regenerative Medicine Xcellerex Xenetic Biosciences Yonsei University Zimmer Notes for Editors About visiongain Visiongain is one of the fastest growing and most innovative independent media companies inEurope. Based inLondon, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors. Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on. If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100